{{Rsnum
|rsid=2269577
|Gene=XBP1
|Chromosome=22
|position=28800769
|Orientation=plus
|GMAF=0.4486
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=XBP1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 6.2 | 46.2 | 47.7
| HCB | 37.8 | 46.7 | 15.6
| JPT | 40.9 | 54.5 | 4.5
| YRI | 36.5 | 52.4 | 11.1
| ASW | 0.0 | 0.0 | 0.0
| CHB | 37.8 | 46.7 | 15.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

[[Vitiligo]]

http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000523

OR = 1.18, 95% CI = 1.06–1.32

{{PMID Auto
|PMID=19543371
|Title=Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo.
|OA=1
}}

{{PMID Auto
|PMID=21085187
|Title=Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP.
|OA=1
}}

{{PMID Auto
|PMID=23510626
|Title=XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}